Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

HOUSTON--(BUSINESS WIRE)--May 25, 2023--

Related Keywords

Chicago ,Illinois ,United States ,Texas ,American ,Imran Alibhai ,Sara Manning ,Apostoliam Tsimberidou ,American Society Of Clinical Oncology ,Tvardi Therapeutics Inc ,American Society ,Clinical Oncology ,Poster Discussion Session ,Targeted Agents ,Session Display Date ,Board Number ,Discussion Session Date ,Tvardi Investor ,Business Wire ,